VIYASH Viyash Scientific Q4 FY26 results (Jan–Mar 2026) and concall
Viyash Scientific Limited reported a transformative FY26, achieving its strongest quarter in Q4 with EBITDA exceeding INR200 crores and a significant 1,324% PAT growth for the full year. The company saw robust revenue growth, particularly in formulations, and substantial margin expansion. Management highlighted successful integration, strategic focus on complex products, and expansion in animal health, while also addressing potential challenges from raw material volatility and complex US market dynamics.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 785.7%, net profit up 800.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 42 | 338 | 42 | 328 | 340 +710% | 342 +1% | 372 +786% |
| EBITDA | -2 | 58 | -3 | 49 | 52 +2700% | 70 +21% | 63 +2200% |
| Net profit | 4 | 51 | 4 | 17 | 23 +475% | 0 −100% | 36 +800% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
